Carmel Wroth
Carmel Wroth is a senior health editor for NPR's Science Desk, where she guides digital strategy for the health team and conceives and edits digital-first, enterprise stories and packages.
Formerly, she founded and managed Side Effects Public Media, a public radio collaborative covering public health in the Midwest. Wroth also served as an editor at Yoga Journal for five years.
-
What's the U.S. doing to watch out for the omicron variant? Here's the work underway and the challenges that experts say may slow down the country's efforts. -
Many Americans are now eligible for a COVID vaccine booster. Are you? Our quiz will help you figure it out.
-
With the back and forth on boosters from government agencies, many Americans are wondering if they really need an extra shot. Here is what the science says about who needs a booster now — and why. -
People with weakened immune systems who already got two doses of the Pfizer or Moderna COVID-19 vaccines can now get a third shot. But exactly who is eligible? Here's what we know so far. -
As the delta variant takes over in the U.S., new, localized outbreaks are emerging. Those surges are likely driven by pockets of dangerously low vaccination rates.
-
An independent federal advisory committee to the CDC recommends the Pfizer-BioNTech vaccine for people over 16. But state health leaders say distribution and funding challenges remain. -
The President's diagnosis calls for contact tracing on a massive scale. Luckily, not everyone President Trump saw this week with is a high risk exposure. Here's who is. -
As schools weigh the risks of reopening, many are making plans to lower the risks of coronavirus transmission. Here's how to vet your school's proposals. -
New estimates say the U.S. needs to triple its testing. But how much testing does each state need? Here's how states compare to each other, and to targets experts say they should hit. -
The preliminary results showed that hospitalized patients who received remdesivir recovered 31% faster. Dr. Anthony Fauci hailed the findings as "quite good news."
